Apollomics (APLM) Competitors $6.23 +0.08 (+1.30%) Closing price 04:00 PM EasternExtended Trading$6.29 +0.06 (+0.96%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. ENLV, SCYX, PMN, RANI, MIRA, CLSD, NNVC, FBLG, NRSN, and QTTBShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Enlivex Therapeutics (ENLV), SCYNEXIS (SCYX), Promis Neurosciences (PMN), Rani Therapeutics (RANI), MIRA Pharmaceuticals (MIRA), Clearside Biomedical (CLSD), NanoViricides (NNVC), FibroBiologics (FBLG), NeuroSense Therapeutics (NRSN), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors Enlivex Therapeutics SCYNEXIS Promis Neurosciences Rani Therapeutics MIRA Pharmaceuticals Clearside Biomedical NanoViricides FibroBiologics NeuroSense Therapeutics Q32 Bio Enlivex Therapeutics (NASDAQ:ENLV) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment. Do analysts prefer ENLV or APLM? Enlivex Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 791.27%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Apollomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Apollomics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of ENLV or APLM? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, ENLV or APLM? Enlivex Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Does the media favor ENLV or APLM? In the previous week, Enlivex Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.89 beat Enlivex Therapeutics' score of 0.63 indicating that Apollomics is being referred to more favorably in the news media. Company Overall Sentiment Enlivex Therapeutics Positive Apollomics Very Positive Is ENLV or APLM more profitable? Apollomics' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Apollomics N/A N/A N/A Which has preferable valuation & earnings, ENLV or APLM? Enlivex Therapeutics has higher earnings, but lower revenue than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.70Apollomics$1.49M4.60-$53.86MN/AN/A SummaryEnlivex Therapeutics beats Apollomics on 7 of the 13 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.85M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1828.1120.03Price / Sales4.60337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book1.398.368.655.90Net Income-$53.86M-$55.19M$3.25B$258.66M7 Day Performance0.32%5.89%4.20%2.23%1 Month Performance-1.11%17.63%10.83%12.77%1 Year Performance-69.65%5.10%34.67%19.36% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics1.0438 of 5 stars$6.23+1.3%N/A-69.3%$6.85M$1.49M0.0045Positive NewsGap UpENLVEnlivex Therapeutics2.8112 of 5 stars$1.19+0.1%$10.00+739.6%-19.6%$28.74MN/A-1.8470News CoverageAnalyst ForecastGap UpSCYXSCYNEXIS0.9054 of 5 stars$0.72+0.9%N/A-63.5%$28.02M$3.75M-1.2860Positive NewsPMNPromis Neurosciences2.9746 of 5 stars$0.84-24.7%$4.33+414.0%-56.9%$27.72MN/A-16.965News CoverageAnalyst RevisionHigh Trading VolumeRANIRani Therapeutics2.3416 of 5 stars$0.44+4.3%$7.33+1,574.3%-82.4%$27.69M$1.03M-0.44110Gap UpMIRAMIRA Pharmaceuticals2.5884 of 5 stars$1.66-1.2%$14.00+743.4%-26.3%$27.66MN/A-3.212CLSDClearside Biomedical2.0571 of 5 stars$0.35+2.1%$4.20+1,113.9%-53.1%$27.28M$3.76M-0.8630High Trading VolumeNNVCNanoViricides0.354 of 5 stars$1.69-0.3%N/A-31.3%$27.08MN/A-2.3420FBLGFibroBiologics3.8153 of 5 stars$0.66-0.5%$13.00+1,857.8%-86.2%$26.35MN/A-3.1610Positive NewsGap UpNRSNNeuroSense Therapeutics2.7267 of 5 stars$1.92-0.6%$14.00+629.5%+144.9%$26.18MN/A-3.5510QTTBQ32 Bio2.5162 of 5 stars$2.14-1.9%$12.17+468.8%-93.6%$26.06M$1.16M-0.4339 Related Companies and Tools Related Companies Enlivex Therapeutics Competitors SCYNEXIS Competitors Promis Neurosciences Competitors Rani Therapeutics Competitors MIRA Pharmaceuticals Competitors Clearside Biomedical Competitors NanoViricides Competitors FibroBiologics Competitors NeuroSense Therapeutics Competitors Q32 Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
